SI1959955T1 - Postopek zdravljenja abnormalne celične rasti - Google Patents

Postopek zdravljenja abnormalne celične rasti

Info

Publication number
SI1959955T1
SI1959955T1 SI200630864T SI200630864T SI1959955T1 SI 1959955 T1 SI1959955 T1 SI 1959955T1 SI 200630864 T SI200630864 T SI 200630864T SI 200630864 T SI200630864 T SI 200630864T SI 1959955 T1 SI1959955 T1 SI 1959955T1
Authority
SI
Slovenia
Prior art keywords
cell growth
abnormal cell
treating abnormal
treating
growth
Prior art date
Application number
SI200630864T
Other languages
English (en)
Slovenian (sl)
Inventor
James Gail Christensen
Yahong Zou
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SI1959955T1 publication Critical patent/SI1959955T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200630864T 2005-12-05 2006-11-23 Postopek zdravljenja abnormalne celične rasti SI1959955T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74276605P 2005-12-05 2005-12-05
US86463706P 2006-11-07 2006-11-07
PCT/IB2006/003397 WO2007066187A2 (en) 2005-12-05 2006-11-23 Method of treating abnormal cell growth
EP06820997A EP1959955B1 (en) 2005-12-05 2006-11-23 Method of treating abnormal cell growth

Publications (1)

Publication Number Publication Date
SI1959955T1 true SI1959955T1 (sl) 2011-02-28

Family

ID=38123250

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630864T SI1959955T1 (sl) 2005-12-05 2006-11-23 Postopek zdravljenja abnormalne celične rasti

Country Status (20)

Country Link
US (1) US7825137B2 (enExample)
EP (1) EP1959955B1 (enExample)
JP (1) JP4619346B2 (enExample)
KR (1) KR101026676B1 (enExample)
AR (1) AR056832A1 (enExample)
AT (1) ATE488237T1 (enExample)
AU (1) AU2006323027B2 (enExample)
BR (1) BRPI0619424B1 (enExample)
CA (1) CA2632286C (enExample)
CY (1) CY1110931T1 (enExample)
DE (1) DE602006018354D1 (enExample)
DK (1) DK1959955T3 (enExample)
IL (1) IL191471A (enExample)
NZ (1) NZ568654A (enExample)
PL (1) PL1959955T3 (enExample)
PT (1) PT1959955E (enExample)
RU (1) RU2384331C2 (enExample)
SI (1) SI1959955T1 (enExample)
TW (1) TWI321050B (enExample)
WO (1) WO2007066187A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005020465D1 (de) * 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
RS52902B (sr) * 2005-08-24 2014-02-28 Eisai R & D Management Co. Ltd. Novi piridinski derivati i pirimidinski derivati (3)
AU2006323025B2 (en) * 2005-12-05 2012-07-05 Pfizer Products Inc. Polymorphs of a c-Met/HGFR inhibitor
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
HUE035732T2 (en) 2006-04-14 2018-05-28 Cell Signaling Technology Inc Gene defects and mutant ALK kinase in human solid tumors
AU2007288793B2 (en) * 2006-08-23 2012-04-19 Eisai R & D Management Co., Ltd. Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
JP2009132660A (ja) * 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US20090227556A1 (en) * 2008-01-31 2009-09-10 Eisai R&D Management Co., Ltd. Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
JPWO2009104520A1 (ja) * 2008-02-18 2011-06-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 フェノキシピリジン誘導体の製造方法（２）
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
WO2010064300A1 (ja) * 2008-12-02 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 食道癌治療用組成物
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
DE102009004061A1 (de) 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
MX2012008550A (es) 2010-02-05 2012-09-07 Merck Patent Gmbh Derivados de hetaril-[1, 8]naftiridina.
CA2780922A1 (en) * 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
WO2012003912A1 (en) 2010-07-05 2012-01-12 Merck Patent Gmbh Bipyridyl derivatives useful for the treatment of kinase - induced diseases
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
CA2829025A1 (en) * 2011-03-03 2012-09-07 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
MX2013010163A (es) 2011-03-09 2013-10-30 Merck Patent Gmbh Derivados de pirido[2,3-b] pirazina y sus usos terapeuticos.
KR20140069181A (ko) * 2011-09-21 2014-06-09 텔리진 엘티디. 키나아제 억제제인 피리딘 화합물
HUE031624T2 (en) 2012-01-31 2017-07-28 Daiichi Sankyo Co Ltd Pyridone derivative
PE20142339A1 (es) 2012-03-06 2015-01-15 Pfizer Derivados macrociclicos para el tratamiento de enfermedades
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
EP2838998B1 (en) 2012-04-18 2017-10-11 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
CN103509008A (zh) * 2012-06-22 2014-01-15 康瑟特制药公司 吡唑取代的氨基-杂芳基化合物的衍生物
WO2014020467A2 (en) 2012-07-30 2014-02-06 Fresenius Kabi Oncology Ltd Process for the preparation of pyrazole substituted aminoheteroaryl compounds
US9651555B2 (en) 2012-09-24 2017-05-16 Ventana Medical Systems, Inc. Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker
US9206166B2 (en) * 2012-11-06 2015-12-08 SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES Certain protein kinase inhibitors
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EA201201654A1 (ru) * 2012-12-28 2014-06-30 Ооо "Эн.Си.Фарм" Противоопухолевое средство (варианты)
WO2014115169A2 (en) * 2013-01-24 2014-07-31 Hetero Research Foundation Crizotinib solid dispersion
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
WO2014140159A1 (en) * 2013-03-13 2014-09-18 Ratiopharm Gmbh Dosage form comprising crizotinib
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
JP6291179B2 (ja) * 2013-07-26 2018-03-14 関東化學株式会社 光学活性２級アルコールの製造方法
US20160214961A1 (en) * 2013-09-10 2016-07-28 Shilpa Medicare Limited Novel salts of crizotinib and their preparation
RU2550346C2 (ru) 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
TWI690525B (zh) 2014-07-07 2020-04-11 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
WO2016032927A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
JP6659554B2 (ja) 2014-08-28 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 高純度キノリン誘導体およびその製造方法
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
US12066428B2 (en) * 2015-11-20 2024-08-20 Agilent Technologies, Inc. Cell-substrate impedance monitoring of cancer cells
KR102369735B1 (ko) 2016-05-20 2022-03-02 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 암을 치료하기 위한 면역요법과의 글루타메이트 조정제의 용도
GB201616116D0 (en) * 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN108047231B (zh) * 2018-01-02 2020-02-11 江苏医药职业学院 [1,2,4]三嗪并[6,1-a]异吲哚化合物的盐酸盐及其应用
IT201800003875A1 (it) * 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JPH07109260A (ja) 1993-10-12 1995-04-25 Fuji Photo Film Co Ltd ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法
ES2161290T3 (es) * 1995-03-30 2001-12-01 Pfizer Derivados de quinazolina.
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
CN101481359A (zh) * 1999-04-15 2009-07-15 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
EP1206265B1 (en) * 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
KR20080021603A (ko) * 2000-02-16 2008-03-07 뉴로젠 코포레이션 치환된 아릴피라진
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6992087B2 (en) * 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
DK2476667T3 (da) * 2003-02-26 2014-09-15 Sugen Inc Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
US8084457B2 (en) * 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
CA2565446A1 (en) * 2004-05-05 2005-12-01 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
CA2578075A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
ATE492544T1 (de) * 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DE602005020465D1 (de) * 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
AU2006323025B2 (en) * 2005-12-05 2012-07-05 Pfizer Products Inc. Polymorphs of a c-Met/HGFR inhibitor

Also Published As

Publication number Publication date
WO2007066187A2 (en) 2007-06-14
PT1959955E (pt) 2011-01-04
ATE488237T1 (de) 2010-12-15
NZ568654A (en) 2012-02-24
US7825137B2 (en) 2010-11-02
TW200727899A (en) 2007-08-01
KR101026676B1 (ko) 2011-04-04
EP1959955B1 (en) 2010-11-17
CA2632286A1 (en) 2007-06-14
RU2384331C2 (ru) 2010-03-20
WO2007066187A3 (en) 2008-01-17
BRPI0619424A2 (pt) 2011-10-04
TWI321050B (en) 2010-03-01
AU2006323027A1 (en) 2007-06-14
IL191471A (en) 2013-03-24
DK1959955T3 (da) 2011-02-07
IL191471A0 (en) 2009-08-03
KR20080072965A (ko) 2008-08-07
CA2632286C (en) 2011-11-15
EP1959955A2 (en) 2008-08-27
US20080300273A1 (en) 2008-12-04
BRPI0619424B1 (pt) 2022-02-08
AU2006323027B2 (en) 2012-08-02
AR056832A1 (es) 2007-10-24
PL1959955T3 (pl) 2011-04-29
CY1110931T1 (el) 2015-06-10
HK1126121A1 (en) 2009-08-28
JP2007153894A (ja) 2007-06-21
RU2008122471A (ru) 2009-12-10
JP4619346B2 (ja) 2011-01-26
DE602006018354D1 (de) 2010-12-30

Similar Documents

Publication Publication Date Title
IL191471A0 (en) Method of treating abnormal cell growth
IL191555A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EP1906980A4 (en) METHOD OF TREATING OR MANAGING STRESS
TWI369205B (en) Sulfonyl amide derivatives for the treatment of abnormal cell growth
GB0521944D0 (en) Method of treating gas
IL186895A0 (en) Methods for treating eye conditions
IL183889A0 (en) Treatment method
ZA200901364B (en) Method of treatment of photodermatoses
IL184262A (en) A method for culturing cells in culture
ZA200804777B (en) Method of treating abnormal cell growth
ZA200608394B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EP1959972A4 (en) PROCESS FOR TREATING OPEN INJURIES BY HYPOCHLOROUS ACID
GB0607293D0 (en) Plant treatment method
EP1867714A4 (en) 5-FLUORURACIL RESISTANT BACTERIA AND METHOD FOR THE PRODUCTION THEREOF
EP2092054A4 (en) METHOD FOR CONTROLLING THE GROWTH OF A CELL CULTURE
ZA200706873B (en) Method of inhibiting the growth of microorganisms
ZA200803526B (en) Process for stabilization of bacterial cells
GB0602958D0 (en) Method for treating plants
ZA200801827B (en) Method of controlling plants
EP2303335A4 (en) METHOD FOR TREATING HEARING LOSS USING XIAP
EP1954801A4 (en) METHOD FOR ISOLATING CELLS
AU2005900620A0 (en) Method of Treating Biosolids
TWI319188B (en) Method of operating multi-level cell
AU2005900447A0 (en) Method of growing cells
GB0503520D0 (en) Method of treating soil